Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Non-Thioredoxin (Non-TXN) mRNAs with partial seed complementarity represent a broad class of unintended genetic targets for RNA interference (RNAi) therapeutics originally designed to silence the Thioredoxin (TXN) gene. This phenomenon occurs when the 'seed region' of an siRNA or miRNA mimic—typically nucleotides 2 through 8—exhibits complementarity to sequences within the 3' untranslated regions (UTRs) of various cellular mRNAs other than the intended TXN transcript (Jackson et al., 2003). Binding of the RISC complex to these off-target sites can lead to mRNA degradation or translational inhibition, mimicking the natural regulatory mechanism of microRNAs (Birmingham et al., 2006). Because a single siRNA can potentially interact with hundreds of different transcripts through this seed-mediated mechanism, it poses a significant challenge for drug specificity and safety (Setten et al., 2019). These off-target effects can lead to false positives in functional genomics screens and unintended toxicities in clinical applications (Burchard et al., 2009). Strategies to mitigate these effects include chemical modifications of the siRNA backbone, such as 2'-O-methyl substitutions, to destabilize off-target binding (Jackson et al., 2006). Identifying and minimizing these interactions is a critical step in the development of RNA-based drugs to ensure therapeutic efficacy and patient safety.
These transcripts are silenced via the RNA-induced silencing complex (RISC) when an siRNA's seed region (nucleotides 2-8) binds to complementary sequences in their 3' untranslated regions (UTRs).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Non-Thioredoxin messenger RNAs with partial seed complementarity (Non-TXN mRNAs).